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Cytomegalovirus (CMV) reactivation may lead to CMV disease associated with high morbidity and mortality
in patients after hematopoietic stem cell transplantation (HSCT); the identiﬁcation of clinically relevant
markers may aid in the identiﬁcation of patients at increased risk for developing CMV-associated compli-
cations. We evaluated the phosphorylation of signal transducer and activator of transcription 5 (STAT5) in
CD4þ T cells, CD8þ T cells, and TCRgd T cells in response to stimulation with IL-7 or IL-2 after HSCT by
analyzing blood samples taken monthly 1 to 6 months after HSCT. Patients were monitored weekly with a
quantitative PCR from the time of engraftment for CMV viral load in whole blood until at least day 100 after
HSCT. We identiﬁed a correlation between clinical outcome regarding CMV replication and the ability to
respond to IL-7 and IL-2 deﬁned by STAT5 phosphorylation (pSTAT5). Patients with recurrent or prolonged
CMV replications had signiﬁcantly lower pSTAT5 upon stimulation of T cells with either IL-7 or IL-2 at time
points 1 through 3 than those without CMV replication (P < .05). This was also found after stimulation of
CD8þ T cells at time point 2 (P < .05). We conclude that reduced responses to IL-7, reﬂected by pSTAT5, may
represent a clinically relevant functional biomarker for individuals at increased risk for CMV reactivation; our
data may also aid in designing better strategies to improve anti-CMV immune responses without increasing
the risk of developing graft-versus-host disease.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION
Human cytomegalovirus (CMV) is a ubiquitous virus
infecting more than 50% of the adult population [1]. Human
CMV poses a threat to severely immunosuppressed in-
dividuals, such as patients after allogeneic hematopoietic
stem cell transplantation (HSCT) [2-4] or patients undergo-
ing solid organ (eg, lung) transplantation [5]. CMV reac-
tivation might lead to CMV disease associated with high
morbidity and mortality [2,3], due to failing immune sur-
veillance [6]. CMV viral load, most commonly measured by
quantitative PCR, is routinely monitored after HSCT [2,4,7]
and used as the basis for pre-emptive antiviral therapy that
is usually effective [2,8]. However, patients experiencingedgments on page 131.
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13.10.006repeated episodes of CMV replication are at an increased risk
for CMV disease [2]. Furthermore, the currently available
antiviral agents have signiﬁcant limitations, particularly
bonemarrowand renal toxicity [8]. Therefore, there is still an
unmet clinical need to identify patients at increased risk
to develop CMV disease or recurrent CMV reactivation
requiring prolonged monitoring and repeated courses of
anti-CMV treatment [6,9].
Delayed or poor immune reconstitution of CMV-speciﬁc
T cells is associated with increased risk of CMV disease
and transplantation-related mortality [6]. IL-7emediated
signaling via the IL-7 receptor (IL-7R) helps to improve and
speed up immune reconstitution [10]. IL-7 is required for
early ampliﬁcation and survival of lymphoid lineage pro-
genitors [11,12]. It rescues T cells from activation-induced cell
death associated with the up-regulation of T lymphocyte
survival factors and induces phosphorylation of signal
transducer and activator of transcription 5 (STAT5) in T cells
[13] activating STAT, which then enters the nucleus and binds
to speciﬁc DNA sequences in the promoter regions of genes,
resulting in gene activation or suppression [14]. CD4þ or
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STAT5 phosphorylation (pSTAT5) and show a fast and strong
response to IL-2 or IL-7 stimulation. Decreased response to
IL-7 was deﬁned by absence of pSTAT5, which has been
associated with decreased immune functions, such as
decreased cytokine production [15]. Increased constitutive
pSTAT5 has been associated with chronically activated T cells
[16]. Furthermore, the IL-7eIL-7R axis has been found to be
crucial for maintenance and expansion of CMV-speciﬁc
immune responses [17].
Therefore, we evaluated the function of the IL-7 signaling
pathway by measuring phosphorylation of STAT5 in T cells
(CD4þ and CD8þ) and TCRgd T cells in response to stimula-
tionwith IL-2 and IL-7 in peripheral blood mononuclear cells
(PBMCs) obtained from 40 HSCT patients. The association of
cytokine-induced STAT5 phosphorylation was studied with
the CMV status, deﬁned by quantitative PCR and the devel-
opment of graft-versus-host disease (GVHD).
MATERIAL AND METHODS
Study Design
This was a prospective, longitudinal clinical cohort study. The patients,
all suffering from hematologic malignancies, and/or the stem cell donors
were CMV-seropositive. Patients were informed regarding study participa-
tion and provided informed consent. The study was approved by the
regional ethical committee in Stockholm (Ethical permit: 2006/645-31/3).
Blood Samples
Blood samples were drawn monthly within the ﬁrst 3 months after
HSCT (time point 1 to 3); additional samples at the fourth to sixth month
after HSCT (time point 4 to 6) were drawn from patients reactivating CMV or
having a primary CMV infection. PBMCs from heparinized blood were iso-
lated by Ficoll separation and immediately frozen and stored in 90% FBS
and10% DMSO in liquid nitrogen. Samples from all time points from each
respective patient were thawed and stained for ﬂow cytometric analysis at a
single laboratory session and analyzed with the Gallios ﬂow cytometer
(Beckman Coulter, San Diego, CA) by the same operator person to avoid
intra-variability. Flow data analysis was performed using Kaluza software
(Beckman Coulter).
CMV Monitoring and Therapy
Patients weremonitored for CMV viral loads with a quantitative PCR on
whole blood from the time of engraftment weekly until day 100 after HSCT.
The PCR technique has been described previously [2,18]. More than
3 months after HSCT, weekly monitoring was continued only in those
patients who had experienced CMV reactivation or had severe GVHD,
whereas the other patients were monitored at an individual basis but
usually at each visit to the transplantation center occurring every 2 to 3
weeks until 6 months after HSCT (18). Pre-emptive antiviral treatment
with either i.v. ganciclovir 5 mg/kg BID or oral valganciclovir 900 mg BID
was given at the center’s chosen intervention limit of >1000 copies/mL
blood. The duration of therapy was a minimum of 2 weeks and was dis-
continued when the CMV viral load was <500 copies/mL. In this study, a
second CMV replication episode was deﬁned as requiring negative moni-
toring results in 2 consecutive samples over a period of at least 8 days in
the absence of antiviral therapy. CMV disease was deﬁned according to
Ljungman et al. [19].
Monoclonal Antibodies and Functional Assays
PBMCs were thawed rapidly; cells were washed, counted, and the
numbers and viability of lymphocytes were calculated using a Casy
Counter. All numbers of cells below refer to viable lymphocytes. To test the
functionality of the IL-7 receptor (CD127) and its response to stimulation
with IL-7 and IL-2, an assay measuring the phosphorylation of STAT5 was
used as described [15,20]. Brieﬂy, after thawing, cells were washed and .3
106 cells per tube were incubated overnight in serum-free medium (AIM-
V; Invitrogen, Carlsbad, Germany) in a CO2 incubator at 37C. On day 2,
cells were either stimulated with 300 ng IL-7 (Cytheris, Paris, France) or
750 IU IL-2 (Chiron, Ratingen, Germany) for 15 minutes at 37C. The third
tube contained noncytokine stimulated immune cells, which served as
controls. Isotype controls were also included by staining with the isotype-
matched Alexa488-conjugated anti-IgG1 isotype control antibody for
pSTAT5. After cytokine stimulation, a cocktail of PE-conjugated anti-TCRgd
(clone B1, Becton Dickinson (BD)), PE Cy7-conjugated anti-CD3 (clone SK7,BD), APC-conjugated anti-CD19 (clone SJ25C1, BD), APC Alexa750 custom
conjugated CD8alpha (clone T8, Beckman Coulter), and V450-conjugated
anti-CD4 (clone RPA-T4, BD) was added. Cells were ﬁxated with 2% para-
formaldehyde and permeabilized with 90% methanol before adding
Alexa488-conjugated anti-pSTAT5 (clone pY694, BD). Samples were
immediately analyzed on a Gallios ﬂowcytometer (Beckman Coulter) using
Kaluza software (Beckman Coulter). Lymphocytes were gated based on
forward and side scatter; from this cell population, CD19CD3þ cells were
gated and subsequently gated for CD4/CD8 to separate CD4þCD8þ cells,
CD4þCD8 cells, CD4CD8 cells, and CD4CD8þ cells. From the
CD19CD3þ T cell population, a gate to segregate TCR gdþ cells was
created. Phosphorylated STAT5 was measured in the T cell populations
listed above. To determine the speciﬁc IL-7 and IL-2 stimulated pSTAT5, the
pSTAT5 values from the unstimulated cells (constitutive pSTAT5) were
subtracted from IL-2 and IL-7 stimulated cells (DSTAT5). Only data with
more than 25 absolute events to be counted were allowed according to the
“Minimal Information About T cell Assays” (MIATA) guidelines (http://
www.miataproject.org/).
Statistics
Risk factors for the number of CMV replication episodes were deter-
mined by multinomial logistic regression. Statistical comparison of each
group was performed using a 1-way ANOVA with multiple comparisons.
Differences over time were analyzed using the Tukey’s multiple compari-
son test and Mann-Whitney test. Comparisons among the CMV reac-
tivation groups (no reactivation, 1 reactivation, multiple, or prolonged
reactivations) at the different time points were made by ANOVA and post-
hoc analysis by t tests. All the reported P values are based on 2-sided
testing. Statistical analysis was performed using Prism 5 and Statistica
software packages.
RESULTS
Patients and CMV Replication Episodes
Forty patients were included in the study and the patient
characteristics are provided in the Supplementary Table 1.
Patients were classiﬁed into 3 cohorts: those without CMV
replication (CMV), those with 1 CMV replication episode
(CMVþ), and those with prolonged or repeated CMV repli-
cation episodes (CMVþþ). Acute GVHD involving skin and
intestines were seen in 25 patients; 16 patients developed
chronic GVHD. As seen in Supplementary Table 1, 9 of 17
(53%) patients with acute GVHD grade II to grade IV devel-
oped CMV replication (CMVþ or CMVþþ) compared with 15
of 23 (65%) in patients with acute GVHD grade 0 to I. Six of 16
of the patients in the CMVþ group had acute GVHD II to IV
compared to 2 of 7 in the CMVþþ group and 9 of 17 in the
CMV group.
Twenty-seven of 40 patients had at least 1 documented
CMV replication episode and 23 of these occurred within
100 days after HSCT. Four patients had late ﬁrst CMV reac-
tivations at 128 days (patient no. 28), 156 days (patient no.
39), 182 days (patient no. 22), and 515 days (patient no. 4);
1 patient who had a brief CMV reactivation at 38 days after
HSCT had a second CMV reactivation at day 711 (patient no.
29). Eight patients had 2 and 1 patient had 3 recurrent CMV
episodes. In addition, 8 patients had prolonged replication
episodes requiring 28 or more days of antiviral treatment.
Three patients developed clinically more complicated CMV
reactivations. One of these 3 patients (patient no. 31, who
belonged to the DRþ group) did not undergo a tissue bi-
opsy for conﬁrmation of CMV disease and died later. This
patient had a prolonged CMV reactivation. The second pa-
tient (patient no. 28, who belonged to the DþRþ group) also
had a prolonged CMV reactivation, but the biopsy showed
only suspect CMV-positive stromal cells in the affected
tissue. The third patient (patient no. 17, also in the DþRþ
group) did show immunohistochemical CMV-positive
stromal cells; however, the clinical assessment at that time
was that the patient did not have CMV disease despite the
biopsy result. This latter patient did not experience
Figure 1. Delta pSTAT5 in different cell populations after stimulation with IL-7 and IL-2 at time points 1 through 3. Signiﬁcant differences in the DpSTAT5 for IL-7 and
IL-2 stimulated T cells (in black) at time points 1 through 3 (P < .05 for all comparisons) were identiﬁed by comparison among the 3 CMV reactivation groups (CMV;
CMVþ; CMVþþ). The DSTAT5 is the difference in increase of frequency in pSTAT5 cells after cytokine induction in comparison to the parental T cell population
(ex vivo T cells) and thereby the DSTAT5 reﬂects the ability of the ex vivo T cells to respond physiologically.
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reactivations were documented 17 to 711 days after HSCT
and of those reactivations, 25 were treated pre-emptively
with anti-CMV drugs, whereas 12 reactivations were in
patients who had viral loads below the set limit for antiviral
therapy or they occurred later after HSCT in patients
without risk factors for CMV disease.
Risk factors for development of at least 1 CMV replication
episode were the use of unrelated stem cell donors (P < .01)
and CMV serological status (P ¼ .04). Factors without inﬂu-
ence on CMV replication were age, stem cell source,
conditioning intensity, acute GVHD, or chronic GVHD. Lym-
phopenia, deﬁned as <.3  109 lymphocytes/L blood, was
seen in 7 of the 40 patients. One patient had lymphopenia at
the second time point and all other patients at the ﬁrst time
point. Five lymphopenic patients belonged to the CMV-
group (representing 33% of the CMV group), and 3 to the
CMVþ group (13% of this group). Surprisingly, an absence of
lymphopenia was found in the CMVþþ group.
Ability to Respond to Stimulation with IL-7 and IL-2 at
Cell Population Level
In general, the different patient groups exhibited strong
phosphorylation of STAT5 in CD4þ Tcells, CD8þ Tcells, TCRgd
T cells, CD8þCD4þ (activated) T cells, or (CD3þ) CD4CD8 T
cells upon stimulationwith IL-2 or IL-7 as compared with theconstitutive pSTAT5 (Supplementary Figures 1 and 2)
regardless of the CMV reactivation pattern.
The comparison of the 3 CMV reactivation groups
(CMV, CMVþ, CMVþþ), revealed signiﬁcant differences in
the DpSTAT5 (ie, difference between constitutive and
cytokine-induced STAT5 phosphorylation) for IL-7 and IL-2
stimulated T cells at time points 1 to 3 (P < .05 for all
comparisons) (Figure 1). When we compared the different
CMV reactivation groups, the CMVþþ group had signiﬁ-
cantly lower DpSTAT5 after stimulation of T cells with either
IL-7 or IL-2 at time points 1 to 3 than the CMV group (P <
.05) (Figure 1). This was also found after stimulation of
CD8þ T cells at time point 2 (P < .05). In addition, we
identiﬁed signiﬁcantly lower DpSTAT5 for IL-2 stimulated
CD8þ cells at time point 3 in the CMVþþ group as compared
with the CMV group and for the CMVþ group compared
with CMV at time point 2. There were no statistical dif-
ferences concerning IL-7 stimulation in DpSTAT5 comparing
the CMV versus CMVþ at time points 1 to 3 or of IL-2 or IL-
7 stimulation in the CMVþ and the CMVþþ groups at time
points 1 to 6 (data not shown).
We could not identify any difference in STAT5 phos-
phorylation in PBMCs from patients with absent or mild
GVHD (GVHD 0 to I) and patients with more severe
GVHD (GVHD II to IV) in CD8þ T cells upon stimulation
with IL-7.
L. Pérez-Bercoff et al. / Biol Blood Marrow Transplant 20 (2014) 128e138 131The frequency of phosphorylated STAT5 in CD4þ T cells
upon IL-7 stimulation was found to be higher in blood from
patients suffering from a more moderate-to-severe GVHD
grade II to IV, but this was seen only at time point 3 (P ¼ .05,
not signiﬁcant) and time point 6 (P < .01) (Supplementary
Figure 3). Of note, patients who did not reactivate CMV
within the ﬁrst 100 days after HSCT were only followed to
time point 3. Therefore, the patient populations analyzed at
timepoints 4 to6only reﬂect thosepatients reactivatingCMV.
Furthermore, regardless of CMV or GVHD, individual Tcell
subsets (ie, TCRgdþ Tcells and CD4þCD8þ Tcells) exhibited a
higher frequency of constitutive STAT5 phosphorylation as
compared to T helper cells (CD4þ) and CD8þ T cells.DISCUSSION
An important controlling mechanism for CMV replication
is T cells. It has been shown that there is a difference in
clinical outcome between detection of CMV-speciﬁc T cells
by tetramers and by functional assays [21]. Gratama et al.
showed that absence of CMV-speciﬁc T cells analyzed by
tetramers was associated with more CMV complications and
a higher transplantation-related mortality [6]. We report in
the current study that patients experiencing repeated or
prolonged CMV reactivations had impaired T cell responses
deﬁned by insufﬁcient STAT5 phosphorylation to IL-7 or IL-2
stimulation of T cells. This impairment was not associated
with GVHD, as we could not identify a correlation between
the grade of GVHD and the functional ability of CD8þ T cells
to respond to IL-7 stimulation. However, we found a statis-
tically signiﬁcant correlationwith detection of repeated CMV
viral replication episodes and the use of unrelated donor
grafts and CMV serological status. This could imply that
gauging levels of phosphorylated STAT5 upon IL-7 stimula-
tion ex vivo, will aid to identify patients at higher risk to
suffering CMV complications. The kinetics of the DpSTAT5
responses (ie, the capacity of the T cells to respond to IL-7
stimulation with STAT5 phosphorylation) in the different
CMV replication groups suggests that patients at increased
risk to contract CMV complications can be identiﬁed as soon
as 8 weeks after HSCT. Subjects with low DSTAT5 phos-
phorylation could then be followed with weekly monitoring
of CMV viral loads for a prolonged period, whereas shorter
monitoring is required in patients with high STAT5 phos-
phorylation. This is in accordance with our previous ﬁndings
that monitoring and use of pre-emptive antiviral therapy can
be safely stopped in patients with existing CMV-speciﬁc
immune responses at 100 days after HSCT [18]. It also con-
ﬁrms the pattern our group found when investigating the
correlation between Epstein-Barr virus post-transplantation
lymphoproliferative disease and decreased IL-7 signaling
[22]. The ﬁndings in the present study, however, need to be
assessed in a larger study. Furthermore, our study reveals
that certain immune cell subsets are constitutively activated
after HSCT; this includes CD4þCD8þ T cells, representing
activated CD4þ T cells, which express the CD8a chain [23] or
TCRgd Tcells that may also play an important role in immune
reconstitution [24] and in CMV-directed cellular immune
responses [25]. We conclude that reduced responses to IL-7
reﬂected by pSTAT5 may represent a clinically relevant
functional biomarker for individuals at increased risk for
CMV reactivation; our data may also aid in the design of
better strategies to improve anti-CMV immune responses
without increasing the risk of developing GVHD [26-28].ACKNOWLEDGMENTS
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NSG mouse modela b s t r a c t
Human cytomegalovirus (HCMV) infection, including primary infection resulting from transmission from a
seropositive donor to a seronegative recipient (Dþ/R), remains a signiﬁcant problem in the setting of pe-
ripheral blood stem cell transplantation (PBSCT). The lack of a suitable animal model for studying HCMV
transmission after PBSCT is a major barrier to understanding this process and, consequently, developing novel
interventions to prevent HCMV infection. Our previous work demonstrated that human CD34þ progenitor cell
eengrafted NOD-scid IL2Rgcnull (NSG) mice support latent HCMV infection after direct inoculation and reac-
tivation after treatment with granulocyte colony-stimulating factor. To more accurately recapitulate HCMV
infection in the Dþ/R PBSCT setting, granulocyte colony-stimulating factoremobilized peripheral blood stem
cells from seropositive donors were used to engraft NSG mice. All recipient mice demonstrated evidence of
HCMV infection in liver, spleen, and bone marrow. These ﬁndings validate the NSG mouse model for studying
HCMV transmission during PBSCT.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION
Despite advances in diagnostics and therapeutics, human
cytomegalovirus (HCMV) remains a signiﬁcant cause of
morbidity andmortality after peripheral blood stem cell (PBSC)
transplantation (PBSCT), and novel approaches to preventing
HCMV infection are needed [1]. HCMV-seronegative recipients
(R) of allografts from HCMV-seropositive donors (Dþ),
although at lower risk for developing HCMV infection and
disease than seropositive recipients (Rþ), will still develop
post-transplantation primary infection in up to 20% of cases
[2-7]. The donor graft is the most important source of virus
early in the post-transplantation period, and a retrospective
analysis of Dþ/R transplantations identiﬁed several factors
associatedwith successful virus transmission [5]. However, the
strict species speciﬁcity of cytomegaloviruses and the conse-
quent lack of a suitable animal model system have hinderedthe experimental validation of these ﬁndings as well as the
development of preventative strategies in this population.
“Humanized” mice, which have undergone trans-
plantation with human cells and/or tissues, have recently
been developed as tools to aid the in vivo study of pathogens
with strict human tropism [8]. We reported the ﬁrst hu-
manized mouse model of HCMV infection in which human
CD34þ hematopoietic progenitor celleengrafted NOD-scid
IL2Rgc
null (NSG) mice directly infected with HCMV supported
latent viral infection, reactivation in human macrophages,
and dissemination after granulocyte colony-stimulating
factor (G-CSF)-induced mobilization of bone marrow he-
matopoietic cells [9]. The present study was carried out to
determine whether NSG mice would also demonstrate
evidence of HCMV infection after transplantation of G-
CSFemobilized PBSCs from HCMV-seropositive donors,
thereby recapitulating Dþ/R PBSCT and validating the NSG
mouse model as a tool for studying HCMV transmission and
infection in this setting.METHODS
Mice
NSG mice were maintained in an speciﬁc pathogen-free facility accord-
ing to procedures approved by Oregon Health and Science University’s
Institutional Animal Care and Use Committee. Before transplantation, mice
